NSE: LAURUSLABS | BSE: 540222

Strong Performer, Getting Expensive

Download real time

837.75 1.25 (0.15%)

High volume today

NSE 25 Jul, 2025 3:31 PM (IST)

45,223.8

Market Cap

High in industry

1.2

Beta 1Year

Very High Volatility

Estimates Beat

Laurus Labs' net profit and revenue beat Forecaster estimates by 55% and 8.2%, respectively See details

Laurus Labs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LAURUSLABS, BSE:540222 Laurus Labs Ltd.

Laurus Labs Ltd.

05 Dec 2016

837.75

0.15%

Laurus Labs Ltd.

IPO Subscribe: Laurus Labs Ltd.

Ashika Research

The company operates in 4 segments: Generics APIs, Generics FDFs, Synthesis and Ingredients. Generics API business comprises the development, manufacture and sale of APIs and advanced intermediates; Generics FDF business comprises the development and manufacture of oral solid formulations; Synthesis business includes contract development and manufacturing services for global pharmaceutical companies; and Ingredients business comprises the manufacture and sale of specialty ingredients for use in the nutraceutical and cosmeceutical sectors....

Laurus Labs Ltd. has an average target of 640.25 from 4 brokers.

Laurus Labs Ltd.

05 Dec 2016

837.75

0.15%

BP Equities Laurus Labs Ltd IPO Note AVOID 5th De

IPO Avoid: Laurus Labs Ltd.

BP Wealth

Laurus Labs Limited (Laurus Labs) was originally incorporated on September 19, 2005 at Hyderabad, Andhra Pradeshas a Private Limited Company. The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited. Laurus Labs Limited (Laurus Labs) is the leading research and development (R&D;) driven pharmaceutical company in India, with a leadership position in Generic Active Pharmaceutical Ingredients (APIs) for select, high-growth Therapeutic areas of Anti-Retrovirals (ARVs) and Hepatitis C. The company also manufacture APIs in Oncology and other Therapeutic areas. The strategic and early investments in R&D; and Manufacturing infrastructure have enabled them to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing Donor-Funded Access-to-Medicines Markets of Sub...

Laurus Labs Ltd. has an average target of 640.25 from 4 brokers.

Laurus Labs Ltd.

05 Dec 2016

837.75

0.15%

Laurus Labs Limited

Laurus Labs Ltd.

SMC online

Incorporated in 2005, Laurus Labs Ltd is Hyderabad based pharmaceutical company. Laurus Labs is in the business of manufacturing generic active pharmaceutical ingredients (APIs) for therapeutic areas of antiretrovirals (ARVs) and Hepatitis C. Company also manufactures APIs in oncology and other therapeutic areas. The company operates in operate in four business lines: Generics APIs, Generics FDFs, Synthesis and Ingredients. The company has also set up a R&D; center in Greater Boston, United States in 2015. As of June 30, 2016, it has employed 587 scientists at its R&D; center in Hyderabad and 12 scientists at its R&D; centre in Greater Boston, which constituted 25.0% of its total...

Laurus Labs Ltd. has gained 93.10% in the last 1 Year

Laurus Labs Ltd.

03 Dec 2016

837.75

0.15%

Laurus Labs is a Hyderabad based company engaged in manufacturing of Active Pharma Ingredients (API). Company derives 80% of its revenues from exports while rest comes from the domestic markets. Its client base features companies like Cipla, Natco, Mylan, etc. API is its largest segment which contributes 92% of the revenues while rest 8% ..

Neutral: Laurus Labs Ltd.

Angel Broking

Laurus Labs is a Hyderabad based company engaged in manufacturing of Active Pharma Ingredients (API). Company derives 80% of its revenues from exports while rest comes from the domestic markets. Its client base features companies like Cipla, Natco, Mylan, etc. API is its largest segment which contributes 92% of the revenues while rest 8% comes from its Synthesis and Ingredients business. Investment rationale 1) Company operates its API business model with a niche focus on select therapeutic segments. This makes it a specialist API manufacturer in a few therapeutic segments. 2) Laurus intends to enter in the US market with its...

Number of FII/FPI investors increased from 259 to 293 in Jun 2025 qtr.

Laurus Labs Ltd.

02 Dec 2016

837.75

0.15%

Laurus Labs - IPO

Laurus Labs Ltd.

ICICI Securities Limited

The offer comprises a fresh issue (| 300 crore) and offer for sale. Net Laurus Labs (Laurus) is a leading Indian active pharma ingredient (API) manufacturer having a leadership position in the therapeutic areas of antiretrovirals (ARVs or anti-AIDS) and Hepatitis C. Laurus also manufactures APIs for oncology and other therapeutic areas. In FY16, nine out of the 10 largest generic pharmaceutical companies in the world (by revenues) were its customers. In FY16, it sold APIs in 32 countries. Laurus also has synthesis and neutraceutical/cosmeceuticals ingredients businesses. The company is planning to foray into the formulation segment. Till date, the...

Laurus Labs Ltd. has gained 25.05% in the last 1 Month

Is Laurus Labs Ltd. worth buying?

1230 Votes:

Buy 79.59%

Sell 10.81%

Hold 9.59%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf

New 52W High today

High volume today

Laurus Labs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LAURUSLABS, BSE:540222 Laurus Labs Ltd.